<p>CSPC PHARMA (01093.HK) announced that the Group's developed chemical Class 1 innovative drug SYH2085 tablets have been approved by the National Medical Products Administration of China to conduct clinical trials in China. The approved clinical indication is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and above</p>

01093

<p>CSPC PHARMA announced that its developed Class 1 innovative chemical drug SYH2085 tablets have been approved by the National Medical Products Administration of China for clinical trials in China. The approved clinical indication is for the treatment of uncomplicated influenza A and B in adults and adolescents aged 12 and older</p>

石药集团创新药 SYH2085 获准开展临床试验